31 results
424B5
SRNEQ
Sorrento Therapeutics, Inc.
23 Oct 13
Prospectus supplement for primary offering
12:00am
trials. There are a limited number of suppliers for raw materials that we use to manufacture our drugs and there may be a need to assess alternate … , and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our
424B5
SRNEQ
Sorrento Therapeutics, Inc.
28 Oct 13
Prospectus supplement for primary offering
12:00am
any control over the process or timing of the acquisition of these raw materials by our manufacturers. Except for the manufacture and supply of Cynviloq … ™, we currently do not have any agreements for the commercial production of these raw materials. Any significant delay in the supply of a product
424B5
SRNEQ
Sorrento Therapeutics, Inc.
7 Oct 13
Prospectus supplement for primary offering
12:00am
of suppliers for raw materials that we use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible … sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Except for the manufacture
424B5
m2upfyx57njdi5bp75
14 Apr 17
Prospectus supplement for primary offering
12:00am
424B5
0cr3ye7 3xoaw
12 Apr 17
Prospectus supplement for primary offering
12:00am